What CorFlow Therapeutics does

CorFlow Therapeutics AG is a privately-held Swiss medical device company founded in 2016 and headquartered in Baar, Switzerland. The company is developing the CoFI (Controlled Flow Infusion) System, a proprietary integrated platform for real-time diagnosis and treatment of microvascular obstruction (MVO) in acute heart attack (STEMI) patients undergoing percutaneous coronary intervention (PCI). MVO is documented to occur in up to 60% of acute MI patients, cannot be detected during the index PCI under current standard of care, and is the most powerful prognostic indicator for adverse outcomes including heart failure re-hospitalization in up to 20% of treated patients.

The CoFI System combines a capital CoFI Console (with proprietary algorithm and GUI), a 6 French guide-compatible infusion-occlusion balloon CoFI Catheter that fits into the standard STEMI workflow using the existing 0.014" pressure wire, and single-use sterile CoFI Cassettes. A proprietary algorithm derives diagnostic parameters from real-time distal coronary back-pressure response to a dynamic infusion sequence, enabling physicians to detect MVO in the cath lab and to deliver therapeutic agents directly into the microcirculation. The platform received FDA Breakthrough Device Designation in October 2019. The first-in-human MOCA I study completed in 2024, the FDA approved the MOCA-II IDE Pivotal Trial in July 2025 (Phase 1 safety/performance met in 19 patients across 5 US and 3 European sites as of April 2026), and a parallel REVITALISE randomized controlled trial (≥250 patients) has been approved across the UK, France, Netherlands, and Spain.

The device remains investigational and CorFlow is pre-revenue. The intended commercial model is a capital-plus-consumable structure: CoFI Console placement at hospitals performing PCI, with recurring per-procedure revenue from CoFI Cassettes. Distribution will be direct enterprise sales to tertiary and quaternary cardiac centers through interventional cardiology KOL-driven adoption, leveraging existing trial sites as early reference accounts. The company has raised approximately €57M+ in cumulative funding, headlined by a €44M Series B in September 2024 led by Broadview Ventures and Panakes Partners, and operates with a senior team carrying deep Medtronic and interventional cardiology pedigree. Manufacturing is supported through BYTEC Medizintechnik GmbH.

Name

CorFlow Therapeutics

Legal name

CorFlow Therapeutics AG

Website

https://corflow.com

Company type

Private

Founded year

2016

Operating status

Operating

Headcount range

11–50 employees

Short description

CorFlow Therapeutics AG is a Swiss medical device company developing the CoFI System, a proprietary integrated platform for real-time diagnosis and treatment of microvascular obstruction in STEMI heart attack patients undergoing PCI. Pre-revenue, the company is currently advancing pivotal trials across the US and Europe.

Ownership category

akta.pro rank

Product category

Interventional Cardiology Medical Devices

NAICS

Medical Equipment and Supplies Manufacturing (3391), Electromedical and Electrotherapeutic Apparatus Manufacturing (334510), Measuring, Dispensing, and Other Pumping Equipment Manufacturing (333914)

SIC

Surgical & Medical Instruments & Apparatus (3841), Electromedical & Electrotherapeutic Apparatus (3845), Pumps & Pumping Equipment (3561)

akta.pro primary industry

Interventional Cardiology (PCI/Structural Heart) (HLAKABAB)

akta.pro secondary industries

Hemodynamic Monitoring & Cardiac Diagnostics (Cath Lab, FFR/IVUS/OCT) (HLAHAFAI), Infusion Sets, Catheters & Pump Consumables (HLAHAIAH)

Keywords

• Interventional cardiology devices
• Microvascular obstruction diagnostics
• Coronary microcirculation assessment
• PCI procedure medical devices
• Cardiac catheterization equipment

Headquarters

HQ city

Baar

HQ country

Switzerland

HQ region

Europe

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations, Marketing or Sales, Supply Chain

Revenue model

1. Medical Device and Consumable Sales: Revenue from sale of CoFI Console (capital equipment) and single-use diagnostic cassettes. The consumables model provides recurring revenue from each procedure. Additional revenue potential from professional services for training and implementation support.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels4 records

Core offering

CorFlow Therapeutics develops and manufactures the CoFI (Controlled Flow Infusion) System, a proprietary integrated medical device platform for real-time diagnosis and treatment of microvascular obstruction (MVO) in heart attack patients undergoing percutaneous coronary intervention (PCI). The system combines a capital console, a single-use sterile cassette, an infusion-occlusion balloon catheter, and a proprietary diagnostic algorithm that measures microvascular resistance to identify MVO during the index PCI procedure.

Product overview

CorFlow Therapeutics offers the CoFI (Controlled Flow Infusion) System as its primary product platform. The system consists of three integrated components: the CoFI Console (capital equipment serving as an infusion pump with proprietary algorithm), the CoFI Catheter (infusion-occlusion balloon catheter), and the CoFI Cassette (single-use sterile cassette). The CoFI System is designed to diagnose microvascular obstruction (MVO) in real-time during PCI procedures and serve as a treatment platform for targeted intracoronary infusion of therapeutic agents. It is the first technology to enable physicians to measure microvascular function directly in the cath lab.

Differentiator

Problem solved

Functional benefit

Products and services

• CoFI System (Controlled Flow Infusion System) An integrated diagnostic and therapeutic medical device platform for interventional cardiologists and hospitals performing PCI procedures on STEMI heart attack patients. The CoFI System uses a proprietary algorithm to measure real-time distal coronary back-pressure response, enabling physicians to diagnose microvascular obstruction during the index procedure and to deliver controlled therapeutic infusions into the microcirculation. The platform integrates a CoFI Console (capital equipment with GUI and infusion pump), CoFI Cassette (single-use sterile disposable), and CoFI Catheter (6 Fr compatible infusion-occlusion balloon catheter).

Quantifiable outcome

• Reduction in heart failure re-hospitalizations in STEMI patients with MVO

Segments2 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability1 record

Feature3 records

Partnerships

One partnership is on record.

• BYTEC Medizintechnik GmbHmanufacturing partnerTechnology or IntegrationManufacturing partner for medical devices. BYTEC Medizintechnik GmbH specializes in development and manufacturing of medical devices and precision components for the healthcare industry.

Scale indicators7 records

Recent moves6 records

Expansion highlights6 records

Direct peers

• HeartFlow: HeartFlow provides non-invasive FFR-CT analysis for assessing coronary artery disease, including microvascular dysfunction. Directly comparable as a coronary microvascular diagnostics platform targeting interventional cardiologists, though its approach is non-invasive imaging vs. CorFlow's catheter-based measurement.
• OpSens: OpSens manufactures the OptoWire, a pressure guidewire used for FFR and diastolic pressure ratio measurements during PCI procedures. Directly comparable as a coronary hemodynamic measurement technology used by interventional cardiologists during the same procedural workflow as CorFlow's CoFI System.
• CathWorks: CathWorks developed the FFRangio system, an angio-based FFR computation technology for real-time coronary physiologic assessment during PCI. Comparable as a catheterization lab-based coronary hemodynamic diagnostic competing for the same interventional cardiology budget and workflow integration.
• ACIST Medical Systems: ACIST (owned by Bracco) provides the RXi system and FFR/IVUS technologies for hemodynamic assessment in the cath lab. Comparable as a provider of diagnostic consoles and catheters used by interventional cardiologists during PCI, with similar capital equipment plus consumables economics.

Broad incumbents

• Abbott: Abbott offers a broad interventional cardiology portfolio including OCT (Optis), IVUS, FFR (PressureWire), and coronary intervention devices. Relevant as a broad incumbent with established cath lab relationships and the resources to enter the MVO diagnostic space either organically or via acquisition.
• Boston Scientific: Boston Scientific has a substantial interventional cardiology portfolio including IVUS, FFR (COMET system), and a broad coronary stent franchise. Comparable as a large incumbent with the R&D capacity, clinical trial infrastructure, and cath lab sales force that could either compete with or acquire emerging MVO diagnostics.
• Medtronic: Medtronic is the global leader in interventional cardiology, with coronary stents, guidewires, and a broad portfolio across coronary and structural heart. Highly relevant as CorFlow CEO Paul Mead spent 18 years at Medtronic, and co-founder Prof. Rothman was Medtronic Coronary CMO, providing deep domain familiarity but also a potential future acquirer/competitor.
• Philips: Philips acquired Volcano Corporation and offers IVUS, IFR, and FFR technologies for coronary physiologic assessment, alongside its broader image-guided therapy portfolio. Comparable as an incumbent with catheterization lab presence and the ability to bundle MVO diagnostics into existing hospital contracts.

Emerging players

• Shockwave Medical (J&J): Shockwave developed intravascular lithotripsy for calcium modification and was acquired by J&J in 2024 for $13B. Relevant as a precedent for how innovative interventional cardiology platforms achieve rapid commercial scale and exit value, demonstrating investor appetite in this category.
• Penumbra: Penumbra develops catheter-based thrombectomy and vascular intervention technologies including coronary aspiration products. Comparable as an emerging medtech that scaled catheter-based interventional cardiology platforms from clinical stage to commercial success.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• Xx.com/corflowthx
• LinkedInlinkedin.com/company/corflow

Compliance1 record

Revenue estimate

Valuation estimate

Number of profiles

Profiles14 records

Funding overview

Funding rounds5 records

Investors12 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about CorFlow Therapeutics